FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041620295> ?p ?o ?g. }

• W2041620295 endingPage "7550" @default.
• W2041620295 startingPage "7544" @default.
• W2041620295 abstract "The vav proto-oncogene product, p95vav or Vav, is primarily expressed in hematopoietic cells and has been shown to be a substrate for tyrosine kinases. Although its function is unknown, Vav shares a region of homology with DBL, an exchange factor for the Rho family of GTP-binding proteins. The presence of this domain and the observation that cells transformed with Vav display prominent stress fibers and focal adhesions similar to those that are observed in RhoA transformed cells suggests that Vav may play a role in regulating the actin cytoskeleton. We have, therefore, examined Vav phosphorylation in platelets, which undergo dramatic cytoskeletal reorganization in response to agonists. Two potent platelet agonists, thrombin (via its G protein-coupled receptor) and collagen (via its interaction with the α2β1 integrin), caused Vav to become phosphorylated on tyrosine. Weaker platelet agonists, including ADP, epinephrine and the thromboxane A2 analog, U46619, did not. The phosphorylation of Vav in response to thrombin was maximal within 15 s and was unaffected by aspirin, inhibitors of aggregation, or the presence of the ADP scavenger, apyrase. Vav phosphorylation was also observed when platelets became adherent to immobilized collagen (via integrin α2β1), fibronectin (via integrin α5β1), and fibrinogen (via integrin αHbβ3). These results show that Vav phosphorylation by tyrosine kinases 1) occurs during platelet activation by potent agonists, 2) also occurs when platelets adhere to biologically relevant matrix proteins, 3) requires neither platelet aggregation nor the release of secondary agonists such as ADP and TxA2, and 4) can be initiated by at least some members of two additional classes of receptors, G protein-coupled receptors and integrins, providing further evidence that both of these can couple to tyrosine kinases. The vav proto-oncogene product, p95vav or Vav, is primarily expressed in hematopoietic cells and has been shown to be a substrate for tyrosine kinases. Although its function is unknown, Vav shares a region of homology with DBL, an exchange factor for the Rho family of GTP-binding proteins. The presence of this domain and the observation that cells transformed with Vav display prominent stress fibers and focal adhesions similar to those that are observed in RhoA transformed cells suggests that Vav may play a role in regulating the actin cytoskeleton. We have, therefore, examined Vav phosphorylation in platelets, which undergo dramatic cytoskeletal reorganization in response to agonists. Two potent platelet agonists, thrombin (via its G protein-coupled receptor) and collagen (via its interaction with the α2β1 integrin), caused Vav to become phosphorylated on tyrosine. Weaker platelet agonists, including ADP, epinephrine and the thromboxane A2 analog, U46619, did not. The phosphorylation of Vav in response to thrombin was maximal within 15 s and was unaffected by aspirin, inhibitors of aggregation, or the presence of the ADP scavenger, apyrase. Vav phosphorylation was also observed when platelets became adherent to immobilized collagen (via integrin α2β1), fibronectin (via integrin α5β1), and fibrinogen (via integrin αHbβ3). These results show that Vav phosphorylation by tyrosine kinases 1) occurs during platelet activation by potent agonists, 2) also occurs when platelets adhere to biologically relevant matrix proteins, 3) requires neither platelet aggregation nor the release of secondary agonists such as ADP and TxA2, and 4) can be initiated by at least some members of two additional classes of receptors, G protein-coupled receptors and integrins, providing further evidence that both of these can couple to tyrosine kinases." @default.
• W2041620295 created "2016-06-24" @default.
• W2041620295 creator A5007351308 @default.
• W2041620295 creator A5043845770 @default.
• W2041620295 creator A5066987101 @default.
• W2041620295 date "1996-03-01" @default.
• W2041620295 modified "2023-10-18" @default.
• W2041620295 title "Thrombin Receptor Activation and Integrin Engagement Stimulate Tyrosine Phosphorylation of the Proto-oncogene Product, p95vav, in Platelets" @default.
• W2041620295 cites W135518686 @default.
• W2041620295 cites W1483690774 @default.
• W2041620295 cites W1487500734 @default.
• W2041620295 cites W1489529085 @default.
• W2041620295 cites W1507048810 @default.
• W2041620295 cites W1513904594 @default.
• W2041620295 cites W1535548497 @default.
• W2041620295 cites W1535696878 @default.
• W2041620295 cites W1540271729 @default.
• W2041620295 cites W1548908535 @default.
• W2041620295 cites W1555561206 @default.
• W2041620295 cites W1564333207 @default.
• W2041620295 cites W1565477787 @default.
• W2041620295 cites W1583486328 @default.
• W2041620295 cites W1595934817 @default.
• W2041620295 cites W1605822460 @default.
• W2041620295 cites W1642347096 @default.
• W2041620295 cites W1656991593 @default.
• W2041620295 cites W1671577927 @default.
• W2041620295 cites W1986543124 @default.
• W2041620295 cites W1988156929 @default.
• W2041620295 cites W1989867656 @default.
• W2041620295 cites W1990500910 @default.
• W2041620295 cites W1991460507 @default.
• W2041620295 cites W1992965538 @default.
• W2041620295 cites W1993913708 @default.
• W2041620295 cites W1994139415 @default.
• W2041620295 cites W2005007281 @default.
• W2041620295 cites W2005523294 @default.
• W2041620295 cites W2012385196 @default.
• W2041620295 cites W2023761542 @default.
• W2041620295 cites W2027810531 @default.
• W2041620295 cites W2039012502 @default.
• W2041620295 cites W2044163708 @default.
• W2041620295 cites W2058100090 @default.
• W2041620295 cites W2059188737 @default.
• W2041620295 cites W2066367871 @default.
• W2041620295 cites W2068727414 @default.
• W2041620295 cites W2070673941 @default.
• W2041620295 cites W2071792321 @default.
• W2041620295 cites W2072984471 @default.
• W2041620295 cites W2074249987 @default.
• W2041620295 cites W2075059983 @default.
• W2041620295 cites W2076069294 @default.
• W2041620295 cites W2076991332 @default.
• W2041620295 cites W2079138949 @default.
• W2041620295 cites W2079749432 @default.
• W2041620295 cites W2081753893 @default.
• W2041620295 cites W2084759193 @default.
• W2041620295 cites W2086021309 @default.
• W2041620295 cites W2117291465 @default.
• W2041620295 cites W2134015622 @default.
• W2041620295 cites W2141445328 @default.
• W2041620295 cites W2149188763 @default.
• W2041620295 cites W2164923114 @default.
• W2041620295 cites W2172972738 @default.
• W2041620295 cites W2176511881 @default.
• W2041620295 cites W2405255551 @default.
• W2041620295 cites W2441853607 @default.
• W2041620295 doi "https://doi.org/10.1074/jbc.271.13.7544" @default.
• W2041620295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8631786" @default.
• W2041620295 hasPublicationYear "1996" @default.
• W2041620295 type Work @default.
• W2041620295 sameAs 2041620295 @default.
• W2041620295 citedByCount "73" @default.
• W2041620295 countsByYear W20416202952013 @default.
• W2041620295 countsByYear W20416202952014 @default.
• W2041620295 countsByYear W20416202952022 @default.
• W2041620295 crossrefType "journal-article" @default.
• W2041620295 hasAuthorship W2041620295A5007351308 @default.
• W2041620295 hasAuthorship W2041620295A5043845770 @default.
• W2041620295 hasAuthorship W2041620295A5066987101 @default.
• W2041620295 hasConcept C119524353 @default.
• W2041620295 hasConcept C11960822 @default.
• W2041620295 hasConcept C170493617 @default.
• W2041620295 hasConcept C185592680 @default.
• W2041620295 hasConcept C195687474 @default.
• W2041620295 hasConcept C203014093 @default.
• W2041620295 hasConcept C2776165026 @default.
• W2041620295 hasConcept C2777292125 @default.
• W2041620295 hasConcept C2777553839 @default.
• W2041620295 hasConcept C2781024287 @default.
• W2041620295 hasConcept C3018697912 @default.
• W2041620295 hasConcept C55493867 @default.
• W2041620295 hasConcept C86803240 @default.
• W2041620295 hasConcept C89560881 @default.
• W2041620295 hasConcept C95444343 @default.
• W2041620295 hasConceptScore W2041620295C119524353 @default.
• W2041620295 hasConceptScore W2041620295C11960822 @default.
• W2041620295 hasConceptScore W2041620295C170493617 @default.

• next